Results 131 to 140 of about 9,288 (216)

Sinonasal and Pulmonary Computed Tomography Images Before and After Triple-Combination Therapy in a Patient with Cystic Fibrosis Without ΔF508 Mutations. [PDF]

Diagnostics (Basel)
Tagliati C, Campagna G, Di Sabatino M, Lanni G, Battista D, Ripani P.   +5 more
europepmc   +1 more source

Comparative efficacy and safety of CFTR modulators for people with cystic fibrosis with phe508del mutation: a systematic review and bayesian network meta-analysis. [PDF]

EClinicalMedicine
Safeer V S M, Behl S, Vaidya PC, Tiwari P, Bharti SK, Nahan N, Kumar Sahu J, Bansal D.   +7 more
europepmc   +1 more source

Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor. [PDF]

Ann Am Thorac Soc
Sagel SD, Poore TS, Wagner BD, Xie J, Heltshe SL, Cross M, Bratcher PE, Taylor-Cousar JL, Wilson A, McBennett K, Morgan SJ, Singh PK, Nichols DP, Kelly A, Solomon GM, PROMISE Study Group.   +15 more
europepmc   +1 more source

CFTR Modulator Response in Nasal Organoids Derived from People with Cystic Fibrosis. [PDF]

Cells
Lo Cicero S, Castelli G, Ceci A, Cerio AM, Blaconà G, Virgulti M, Allushi S, Sette G, Spadaro F, Amato F, Melotti P, Sorio C, Cimino G, Biffoni M, Lucarelli M, Eramo A.   +15 more
europepmc   +1 more source

Non-tuberculous mycobacterial infection in cystic fibrosis before and after initiation of elexacaftor/tezacaftor/ivacaftor: now is not the time to lower the guard. [PDF]

BMJ Open Respir Res
Evans IES, Smith D, Henderson D, Riddles T, Masel P, Moore V, Burke AJ, Thomson RM, Reid DW.   +8 more
europepmc   +1 more source

Real-World Impact of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Italy: A Retrospective Study from a Cystic Fibrosis Center. [PDF]

Pulm Ther
Cipolli M, Thorat T, Pafundi PC, Roggeri A, Roggeri DP, Rossi C, Pintani E, Meneghelli I, Lucca F, Fratoni A, Vega-Hernandez G.   +10 more
europepmc   +1 more source

People with cystic fibrosis with high sputum neutrophil elastase on elexacaftor-tezacaftor-ivacaftor exhibit worse pulmonary function and pro-inflammatory airway milieu. [PDF]

Sci Rep
Cammarata-Mouchtouris A, Giraldo DM, Collins GL, Parrilla MM, Kim SO, Mansour S, Giacalone VD, Cottrill KA, Tirouvanziam R, Chandler JD.   +9 more
europepmc   +1 more source

Persistence of lung hyperinflation and small airway dysfunction in school-aged children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: results from the real-world MODUL-CF study. [PDF]

ERJ Open Res
Colin L, Delaup V, Le Bourgeois M, Neve V, Wizla-Derambure N, Ioan IC, Tatopoulos A, Kieffer S, Blonde A, Bokov P, Houdoin V, Le Clainche L, Barzic A, Ohlmann C, Toin T, Perrin T, Coutier L, Abou Taam R, Bonnel AS, Rignani A, Feghali H, Bui S, Fayon M, Letierce A, Sermet-Gaudelus I, Reix P.   +25 more
europepmc   +1 more source

The cystic fibrosis airway cytokine interleukin-1β enhances cystic fibrosis transmembrane conductance regulator modulator efficacy. [PDF]

ERJ Open Res
Gentzsch M, Boyles SE, Minges JT, Cholon DM, Okuda K, Ribeiro CMP.   +5 more
europepmc   +1 more source